{"entity":{"id":"nct03385655","kind":"trial","name":"Prostate Cancer Biomarker Enrichment and Treatment Selection","aka":[],"tldr":"A phase 2 trial of CFI-400945 run by Canadian Cancer Trials Group, active and no longer recruiting.","summary":"Prostate Cancer Biomarker Enrichment and Treatment Selection is a phase 2 interventional study registered as NCT03385655 by Canadian Cancer Trials Group, with 200 participants planned, started 2018-08-01. Conditions recorded: Prostate Cancer. Interventions recorded: Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab and Tremelimumab and Carboplatin.","status":"active","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03385655","url":"https://clinicaltrials.gov/study/NCT03385655"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["cfi-400945"],"companies":["treadwell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03385655","phase":"2","setting":"Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study","sponsor":"Canadian Cancer Trials Group","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03385655/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"cfi-400945","kind":"drug","name":"CFI-400945","route":"/drugs/cfi-400945/"}],"company":[{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/"}]}}